Trials / Withdrawn
WithdrawnNCT01598857
BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Anthera Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when taken with methotrexate in the induction of remission in ANCA-Associated Small Vessel Vasculitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Blisibimod | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2015-06-01
- First posted
- 2012-05-15
- Last updated
- 2015-07-30
Source: ClinicalTrials.gov record NCT01598857. Inclusion in this directory is not an endorsement.